• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 22-Jun-2018
SENSEX
35,689.60
257.21 (0.73%)
NIFTY
10,821.85
80.75 (0.75%)
EQUITY
    No Companies Visited

Back to news list
  • Cipla gains after USFDA approval for generic

    Cipla rose 1.57% to Rs 622 at 9:54 IST on BSE after the company said its subsidiary received US drug regulator's approval to market a generic version of Genzyme's Renvela tablets.

    The announcement was made before market hours today, 27 October 2017.

    Meanwhile, the S&P BSE Sensex was up 71.41 points, or 0.22% to 33,218.54.

    On the BSE, 1.34 lakh shares were traded in the counter so far, compared with average daily volumes of 95,799 shares in the past one quarter. The stock had hit a high of Rs 628 and a low of Rs 618.60 so far during the day. The stock hit a 52-week high of Rs 633.95 on 17 October 2017. The stock hit a 52-week low of Rs 479 on 26 May 2017.

    The stock had outperformed the market over the past one month till 26 October 2017, rising 7.48% compared with 6.38% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 8.33% as against Sensex's 2.59% rise. The scrip had underperformed the market in past one year, rising 4.76% as against Sensex's 18.74% rise.

    The large-cap company has equity capital of Rs 160.94 crore. Face value per share is Rs 2.

    Cipla announced that its subsidiary, InvaGen Pharmaceuticals Inc. (collectively Cipla), has received final approval for its abbreviated new drug application (ANDA) for Sevelamer Carbonate tablets, 800 mg, from the United States Food and Drug Administration (USFDA).

    Sevelamer Carbonate Tablets, 800 mg is a AB-rated generic equivalent to the reference listed drug (RLD), Renvela tablets, 800 mg of Genzyme Corporation and are indicated for the control of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.

    Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health. Commercial launch will commence immediately.

    On a consolidated basis, net profit of Cipla rose 20.57% to Rs 408.82 crore on 3.48% decline in net sales to Rs 3432.32 crore in Q1 June 2017 over Q1 June 2016.

    Cipla is a global pharmaceutical company. Its portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

    Back to news list
Previous Stories :
More
Hot Pursuit News

Quick Links

Since 1986, Capital Market Publishers India Pvt Ltd is undertaking equity research, publishing an investment fortnightly magazine, data-vending and software production. Analysts track industry, companies and the economy. Branches in the metros and major cities ensure comprehensive coverage.

The major strength is equity research. Stock-picking for investor’s portfolio is preceded by rigorous research. The advisory services are transmitted through Capital Market magazine, newsletters, Telefolio. Almost 85% of the scrip’s recommended by us show appreciation. On an average we outperform the Bombay Stock Exchange Sensitive Index twice over, and sometime three times. Our independent status insulates us from influence from brokers and other market participants, ensuring that the selection of stocks and research are unbiased.

We are also pioneers in corporate databases - Capitaline, Mutual Fund database - Navindia

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
91-22-25230011
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine Print Edition queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 23-Jun-2018
  •  ( 10:23) RITES IPO subscribed 67.24 times  
  •  ( 10:22) Fine Organic Industries IPO subscribed 8.99 times  
  •  ( 09:45) Dow jumps more than 100 points, snaps 8-day losing streak  
Show News
22 June 2018 00:00
366.00
(-0.23 %)
1268.20
(1.10 %)
524.65
(2.22 %)
2830.75
(-0.08 %)
374.60
(1.74 %)
265.10
(-0.99 %)
1902.40
(2.54 %)
2081.80
(1.22 %)
3640.10
(0.24 %)
1607.55
(0.87 %)
300.85
(1.11 %)
1954.40
(-0.02 %)
1246.45
(0.01 %)
265.15
(1.67 %)
1320.25
(0.52 %)
1295.50
(0.40 %)
908.15
(2.78 %)
8889.70
(0.22 %)
156.90
(1.26 %)
159.45
(-0.16 %)
197.85
(1.02 %)
1012.30
(-1.94 %)
273.25
(1.69 %)
576.30
(3.91 %)
308.15
(0.52 %)
181.60
(0.69 %)
560.45
(0.40 %)
1811.80
(-0.44 %)
228.65
(-0.20 %)
257.95
(-0.41 %)
335.20
(0.69 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.